Modulim Granted CPT Code from the American Medical Association for its Noninvasive Microvascular Assessment Technology

Irvine, CA — July 30, 2019

(BUSINESS WIRE) — Modulim, the global leader in noninvasive microvascular assessment using spatial frequency domain imaging (SFDI), has announced that the American Medical Association (AMA) has granted a Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) Code (0061U) for the transcutaneous measurement of tissue oxygenation and hemoglobin using SFDI.

The CPT code allows for reimbursement when clinicians use Modulim’s SFDI and multispectral analysis technology to capture, analyze and report the quantitative values and 2D distribution maps for five biomarkers in tissue. This information may be helpful when assessing patients with potential circulatory compromise.

The Centers for Medicare and Medicaid Services (CMS) has priced the PLA code at $27.85 per image on the 2019 Medicare Clinical Laboratory Fee Schedule, effective immediately. The CPT code and pricing will allow healthcare providers to bill and receive payment when testing eligible patients.

” Modulim’s SFDI technology is a vital microvascular assessment tool to identify specific areas of compromised circulation. This can help us manage the care of patients with peripheral artery disease, slow-healing wounds and diabetic foot problems,” said Phillip E. Ward, D.P.M., a podiatrist at Cape Fear Valley Foot and Ankle Center in North Carolina.

CPT codes are granted and maintained by the AMA CPT Editorial Panel and are widely used by government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement.

To request a product demo or for more information about SFDI, visit

1 2019 Medical Clinical Laboratory Fee Schedule is available at

2 CPT is a registered trademark of the American Medical Association.

3Clarifi is a registered trademark of Modulim. See more at

About Modulim

Modulim is a pioneer in subsurface optical imaging powered by SFDI, an advanced imaging technique co-invented by founding CEO and CTO David Cuccia, Ph.D. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue to accurately measure key biomarkers of tissue health and quantifies two key perfusion metrics not identified by any other technology: HbT1 and HbT2. The Clarifi® Imaging System, powered by SFDI, is indicated for measuring tissue oxygenation in patients with potential circulatory compromise. For more information, visit


Gary Marston
VP Sales and Marketing
(949) 825-5075

Paul Williams
Media Relations
(310) 569-0023